000904 CSI Midcap 200 Index
- 4005.46
- +25.26+0.63%
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
There is a differentiation in the small and large-cap style, with the Shanghai-Shenzhen 300 ETF rising and the CSI Midcap 200 Index ETF and China Securities 2000 Index ETF falling this year.
Delisted Yuan Cheng, Delisted Carbon Element, and Delisted Tongda, these three delisted stocks were all collectively resumed trading today, and the stock prices fell sharply. Delisted Yuan Cheng's decline reached 96%, Delisted Carbon Element's declined 83%, and Delisted Tongda's declined 80%. These three companies were all terminated from stock listing by the Shanghai Stock Exchange due to financial problems on May 28th. Last night, all three delisted stocks issued announcements stating that the start date of the delisting arrangement period for their stocks will be June 5th, 2024, and the expected date of the last transaction will be June 26th, 2024. Within five trading days after the expiration of the delisting arrangement period, the exchange will delist the company's stocks.
Maxeon Solar Technologies' Largest Shareholder TCL Zhonghuan Renewable Energy Technology to Invest $97.5M Via a Debt Investment and an Additional $100M Equity Investment
Maxeon's Chief Executive Officer Bill Mulligan noted, "Maxeon has been facing a very difficult market environment since the third quarter of last year, with challenging industry pricing conditions and
Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin
On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.
The Shanghai and Shenzhen Exchange announced that the IPOs of Goerwei and Ola shares were terminated
On the evening of May 27, the Shenzhen Stock Exchange and the Shanghai Stock Exchange respectively terminated the IPO reviews of Goerwei and Ola shares.
Circuit Hyper | Future Intelligent Business Exploration: Individual AI Assistants Equal Rights
GAI's affirmative future commercial value thinking.
Why is it difficult for Fat Donglai to solve Yonghui's questions
Fat Donglai, who was once praised by Lei Jun as “the magic presence of China's retail industry,” has been a bit busy lately. Following the launch of targeted support for*ST Bugao (002251.SZ) in December of last year, Fat Donglai recently took another step to help Yonghui Supermarket (601933.SZ), a leading fresh food supermarket. As soon as news broke that the founder of Fat Donglai visited Yonghui Supermarket's Zhengzhou store on May 8, Yonghui Supermarket immediately reaped a rise and fall, increasing its market value by 2.2 billion yuan. But in reality, Fat Donglai, who set off the secondary market, is only a regional retailer in the far corner of Henan Province. Revenue just broke 10 billion dollars in 2023; Yonghui Supermarket is the industry
Prodelight --- ICT-Link SIP terminal “Yealink” sales partner case study released
Prodelight ＜5580＞ revealed ICT-Link's Yealink introduction and sales partner case study on the 30th. The company provides the cloud telephone system “INNOVERA,” and is taking on the challenge of developing innovative systems. Yealink is a global IP communication equipment manufacturer that focuses on the IP communication area and makes use of high quality, high flexibility, wide compatibility, and speedy specialized technical support. ICT-Link is a good friend
2024 Financial Report | Insulin Low Price Competition, Gan Li Pharmaceutical's Gains and Losses
Go out to sea
Inspur Information's revenue and net profit both declined, and a cash dividend of 190 million yuan was proposed | Financial News
Wave's performance was hampered by the server and parts business. Throughout 2023, Inspur Information's total revenue fell 5.41% year-on-year to 65.867 billion yuan. Net profit attributable to mother decreased by 14.54% year over year to 1,783 billion yuan.
Demand for memory chips picked up, GigaYi innovated both revenue and profit growth in Q1 | Financial News
Q1 net profit increased 36.45% year over year, surpassing the full year of last year.
2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”
Big dividends
Everweft Lithium is in the midst of a battery price war, doubling sales and no increase in profits | Insight Research
On the evening of April 18, Everweft Lithium Energy announced its 2023 annual results. The company's battery market share doubled, but it fell into a dilemma where revenue, net profit, and sales volume diverged. In 2023, Everweft Lithium achieved operating income of 48.78 billion yuan, up 32.38% year on year; net profit to mother was 4.05 billion yuan, up 15.42% year on year, of which net profit from the division's business was 3.54 billion yuan, up 30.19% year on year; after deduction, only 2.23% year on year; gross margin reached 17.04%, up 0.61 percentage points year on year; net interest rate reached 9.27%, down 0.84 hundred percent year on year
“Post-70s” Yuan Jun plans to be the governor of the Bank of Jiangsu
On the evening of April 15, the Bank of Jiangsu issued an announcement. The board of directors of the company agreed to appoint Yuan Jun as the company's president and also agreed to Yuan Jun as a candidate for the company's director. Currently, his qualifications as governor are subject to approval by the supervisory authorities; proposals relating to the company's director candidates still need to be submitted to the company's shareholders' meeting for review and approval. According to his resume, Yuan Jun, male, born in 1971, has a college degree, is an economist, and is currently the deputy party committee secretary of the Bank of Jiangsu. Previously, Yuan Jun served as a non-bank clerk and inspection office clerk in the Jiangsu Branch Audit Office of the People's Bank of China, a clerk at the Nanjing Branch Inspector's Office of the People's Bank of China, and a discipline inspection inspector at the Inspector's Office (
Zoomlion Heavy Industry Science and Technology Reports FY Results
Metals & Mining Monitor | Gold Hits Record High Again; Alamos Gold to Buy Argonaut Gold for $325M, Spin Off Argonaut's Non-Canadian Assets
Hello mooers! Welcome to Mining & Metals Monitor, your source for weekly insights into key commodities and fundamental changes in leading companies.
Hangzhou Tigermed Consulting Reports FY Results
Spending 10 billion dollars, Changdian Technology's China Resources Department is expected to “kill two birds with one stone”
Yellow Finch is in the back
2024 Financial Report | BGI's profit fell by more than 80%, making it difficult to find the next outlet
The era of gold everywhere is over
Backed by Huadong Pharmaceutical, Quanxin Biotech's All in the Field of Self-Immunity | Insight Research
Through a hearing on the Hong Kong Stock Exchange, the secondary market also welcomed a major free player.